TCON News and Press, TRACON Pharmaceuticals Inc. From 05/16/22

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform t...

TRACON Pharmaceuticals, Inc. (TCON) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Charles Theuer – President and Chief Executive Officer Scott Brown – Chief Financial Officer Conference Call Participants Maury Raycroft – Jefferies Ed White ...

Tracon press release (NASDAQ:TCON): Q1 GAAP EPS of -$0.48 misses by $0.06. Cash, cash equivalents and short-term investments were $16.6 million at March 31, 2022, compared to $24.1 million at December 31, 2021. The Company expects that its current cash and cash equivalents will fund operation...

SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platf...

ACOR, ADMA, APP, ASM, ASND, ASYS, ATCO, BAK, BMBL, BROS, BYND, CLPT, CLSD, CPA, CPNG, CYCC, DIS, DOX, ENVX, FLNC, FOSL, FSM, GAIN, GBDC, ICAD, KGC, LGO, LKCO, LTBR, MBII, METC, MFC, MQ, MRAM, MYO, NEON, NOAH, OCX, ONTX, OR, OTRK, PAAS, PAYS, PSTL, OTCPK:PWCDF, RIVN, SAND, SCM, SCTL, SLF, SMTS...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article is excerpted from Tom Yeung’s Moonshot Investor newsletter. To make sure you don’t miss any  of Tom’s potential 100x picks,  subscribe to his mailing list here . A Recession ...

SAN DIEGO, May 04, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform t...

TRACON Pharmaceuticals (NASDAQ:TCON) on Tuesday said the amended protocol to its ENVASARC trial as approved by the U.S. Food and Drug Administration (FDA) in February has been accepted at all 30 clinical sites of the trial in the U.S. and UK. TCON's ENVASARC trial is evaluating antibody envaf...

SAN DIEGO, April 19, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article is excerpted from Tom Yeung’s Moonshot Investor newsletter. To make sure you don’t miss any  of Tom’s potential 100x picks,  subscribe to his mailing list here . Rising Rates...